Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › HIV Infections

HIV Infections

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HIV Infections

579 trials tracked for HIV Infections: 177 in phase 3 or 4 and 53 with published results. The most-cited published study has 6967 citations.

579Trials tracked
177Phase 3 & 4
0Recruiting
53With published results
Phase distribution
Phase 4 59 Phase 3 118 Phase 2 150 Phase 1 83 Other / NA 169
  1. Phase 3 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed · 6,967 cited
  2. Phase 3 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men Completed · 5,150 cited
  3. Phase 3 Botswana TDF/FTC Oral HIV Prophylaxis Trial Completed · 2,030 cited
  4. Phase 3 Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth Completed · 1,426 cited
  5. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) Completed · 383 cited
  6. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) Completed · 382 cited
Show 44 more trials
  1. Phase 3 Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) Completed · 377 cited
  2. Phase 4 Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed · 357 cited
  3. Phase 3 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) Completed · 350 cited
  4. Phase 3 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) Completed · 349 cited
  5. Phase 3 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Completed · 304 cited
  6. Phase 3 Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment Completed · 198 cited
  7. Phase 3 Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) Completed · 171 cited
  8. Phase 3 Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants Completed · 163 cited
  9. Phase 3 Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. Completed · 156 cited
  10. Phase 4 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed · 145 cited
  11. Phase 3 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed · 141 cited
  12. Phase 4 A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy Completed · 128 cited
  13. Phase 4 Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women Completed · 122 cited
  14. Phase 3 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Completed · 118 cited
  15. Phase 3 A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed Completed · 117 cited
  16. Phase 4 Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Completed · 114 cited
  17. Phase 3 HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children Completed · 112 cited
  18. Phase 3 Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection Completed · 112 cited
  19. Phase 4 HIV Persistence and Viral Reservoirs Completed · 98 cited
  20. Phase 3 Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting Completed · 80 cited
  21. Phase 3 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men Completed · 68 cited
  22. Phase 4 PrEP Implementation for Mothers in Antenatal Care Completed · 65 cited
  23. Phase 3 Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults Completed · 64 cited
  24. Phase 3 Vitamin D Supplementation in HIV Youth Completed · 60 cited
  25. Phase 3 Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen Completed · 57 cited
  26. Phase 3 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand Completed · 56 cited
  27. Phase 3 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed · 51 cited
  28. Phase 3 Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa Completed · 50 cited
  29. Phase 4 Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Completed · 46 cited
  30. Phase 3 Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US) Completed · 44 cited
  31. Phase 3 Treatment Options for Protease Inhibitor-exposed Children Completed · 42 cited
  32. Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children Completed · 41 cited
  33. Phase 3 Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women Completed · 37 cited
  34. Phase 4 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) Completed · 32 cited
  35. Phase 3 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women Completed · 28 cited
  36. Phase 3 Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries Completed · 27 cited
  37. Phase 3 A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries Completed · 17 cited
  38. Phase 3 Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs Completed · 13 cited
  39. Phase 3 Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) Completed · 11 cited
  40. Phase 3 Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) Completed · 7 cited
  41. Phase 3 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern Completed · 5 cited
  42. Phase 3 Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy Completed · 3 cited
  43. Phase 4 Anti-HIV Medications for People Recently Infected With HIV Completed · 1 cited
  44. Phase 3 Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents Completed · 1 cited

Showing the 50 most-cited and recently-updated of 579 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

HIV Infections: what the trials found

New evidence indicates the use of Isoniazid in patients with HIV infections [1, 20]. In a large-scale study (N=956), Isoniazid was evaluated regarding safety and pregnancy outcomes; the incidence rates of Grade 3 or higher adverse events related to treatment or causing discontinuation were similar between groups (15.03 vs 14.93), and there were no statistically significant differences in fetal deaths (p=0.093) or premature births (p=0.288) 20.

Other established interventions include the use of Dolutegravir film-coated tablets 3, Raltegravir combined with tenofovir/emtricitabine 22, and Doxycycline 21. Additionally, a combination of maraviroc with two NRTIs showed no statistically significant change in the density of CD3+/CD4+ cells per cubic millimeter at duodenal tissue effector sites following antiretroviral therapy (p>=0.05) 19.

Recent results — preliminary, needs further review

  • CMV-MVA Triplex showed no significant difference in the occurrence of Grade ≥3 adverse events (p=0.79) 4.
  • Cabotegravir sodium (Oral Lead In) was evaluated for concentration at 24 hours following a 30 mg dose 5.
  • Doravirine concentrations were measured during pregnancy, showing significant differences in concentration at 24 hours postdose (p=0.010) 6.
  • Couples Counseling did not show statistically significant differences in viral suppression, exclusive breastfeeding, or postpartum family planning use among female participants (p=0.6, p=0.8, and p=0.5 respectively) 9.
  • Data to care interventions significantly increased the number of clinical visits (p=<.001) and improved medication possession rates (p=<.001), though no significant difference was found in the number of patients initiating or re-initiating ART (p=0.50) 17.

For the clinician treating this condition

  • Isoniazid is established for use in HIV, with safety data showing comparable adverse event rates and pregnancy outcomes across study arms [1, 20].
  • Data-driven care interventions significantly improve clinical engagement and medication adherence among patients 17.
  • Couples counseling did not demonstrate statistically significant impacts on viral suppression or breastfeeding practices in the studied cohort 9.

AI synthesis of 10 cited trials, updated Aug 2, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.